Both CTNNB1 (58% vs. 16%) and AXIN1 (54% vs. 16%) mutations were significantly enriched in patients undergoing a subsequent recurrence of their tumor (P = 0.0045 and P = 0.0022, respectively) (Fig. 2A). This evidence concerns the gene CTNNB1 and neoplasm.